Agios Pharmaceuticals, Inc.
AGIO
$33.51
$0.922.82%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 140.58% | 78.34% | 48.03% | 36.26% | 30.57% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 140.58% | 78.34% | 48.03% | 36.26% | 30.57% |
| Cost of Revenue | 12.27% | 14.35% | 13.24% | 13.54% | 5.21% |
| Gross Profit | 6.20% | -5.67% | -8.51% | -10.74% | -2.35% |
| SG&A Expenses | 8.50% | 11.81% | 14.99% | 28.47% | 39.12% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 10.94% | 13.46% | 13.83% | 18.31% | 15.13% |
| Operating Income | 0.54% | -8.00% | -10.90% | -16.86% | -13.94% |
| Income Before Tax | -159.38% | -159.65% | -157.63% | -156.38% | 290.26% |
| Income Tax Expenses | -102.30% | -102.30% | -102.30% | -116.71% | -- |
| Earnings from Continuing Operations | -163.27% | -163.46% | -161.27% | -159.51% | 278.14% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -163.27% | -163.46% | -161.27% | -159.51% | 278.14% |
| EBIT | 0.54% | -8.00% | -10.90% | -16.86% | -13.94% |
| EBITDA | 0.57% | -8.18% | -11.16% | -17.20% | -14.33% |
| EPS Basic | -161.11% | -161.91% | -160.23% | -158.99% | 276.72% |
| Normalized Basic EPS | -2.13% | -9.47% | -9.25% | -11.11% | -6.01% |
| EPS Diluted | -163.49% | -164.26% | -162.50% | -161.24% | 269.94% |
| Normalized Diluted EPS | -2.72% | -10.12% | -9.91% | -11.80% | -5.40% |
| Average Basic Shares Outstanding | 2.32% | 2.15% | 2.05% | 2.03% | 2.01% |
| Average Diluted Shares Outstanding | 1.66% | 1.48% | 1.38% | 1.36% | 2.67% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |